Key result
Targeting CD47 or Calr/LRP1 pathways restores impaired efferocytosis to limit necrotic core expansion in atherosclerosis.
Why the study?
Does reactivating efferocytosis via targeting 'eat me' or 'don't eat me' ligands reduce necrotic core expansion and plaque progression in atherosclerosis?
Does reactivating efferocytosis via targeting 'eat me' or 'don't eat me' ligands reduce necrotic core expansion and plaque progression in atherosclerosis?
Answers are grounded in this paper and cite their sources.
Impaired efferocytosis is a major driver of atherosclerotic necrotic core growth and vascular inflammation, offering a novel therapeutic target (such as anti-CD47 therapy) to stabilize plaques independently of traditional risk factors.
The necrotic core has long been a hallmark of the vulnerable atherosclerotic plaque. Although apoptotic cells are cleared quickly in almost all other tissue beds, their removal appears to be significantly impaired in the diseased blood vessel. Emerging evidence indicates that this phenomenon is caused by a defect in efferocytosis, the process by which apoptotic tissue is recognized for engulfment by phagocytic cells such as macrophages. Genetic and experimental data suggest that efferocytosis is impaired during atherogenesis caused by dysregulation of so-called eat me ligands, which govern the edibility of cells undergoing programmed cell death. The following is a summary of recent data indicating that efferocytosis is a major unappreciated driver of lesion expansion but also a reversible defect that can potentially be targeted as a means to prevent plaque progression.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2017) conducted a review in Atherosclerosis. Pro-efferocytic therapies (e.g., CD47 blocking antibodies, Calreticulin peptide) was evaluated on Necrotic core expansion and atherosclerotic plaque progression. Impaired efferocytosis (reduced ~20-fold in plaques) drives necrotic core expansion in atherosclerosis, and targeting CD47 or Calr/LRP1 pathways represents a reversible therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: